Research Paper Volume 13, Issue 21 pp 24449—24463

Small interfering RNA-induced silencing lncRNA PVT1 inhibits atherosclerosis via inactivating the MAPK/NF-κB pathway

PVT1 is highly expressed in oxLDL-treated HA-VSMCs. HA-VSMCs were treated with 50 mg/mL oxLDL for 24 hr. (A) Cell viability detected by MTT assay; (B) Levels of TG, TC, HDL, and LDL detected by ELISA; (C) LncRNA PVT1 relative expression detected by qRT-PCR. N = 3. Data were presented as mean ± standard deviation. Pairwise comparisons were analyzed using independent sample t test. * p p oxLDL, oxidative low density lipoprotein; HA-VSMCs, Human arterial vascular smooth muscle cells.

Figure 3. PVT1 is highly expressed in oxLDL-treated HA-VSMCs. HA-VSMCs were treated with 50 mg/mL oxLDL for 24 hr. (A) Cell viability detected by MTT assay; (B) Levels of TG, TC, HDL, and LDL detected by ELISA; (C) LncRNA PVT1 relative expression detected by qRT-PCR. N = 3. Data were presented as mean ± standard deviation. Pairwise comparisons were analyzed using independent sample t test. * p < 0.05, ** p < 0.01. PVT1, plasmacytoma variant translocation 1; oxLDL, oxidative low density lipoprotein; HA-VSMCs, Human arterial vascular smooth muscle cells.